Development of a Scalable, Stereoselective Second-Generation Route for CXCR7 Antagonist ACT-1004-1239 via Chiral Enamine Reduction and a Novel Telescoped Sequence of Transesterific
Gabriel Schäfer Tony Fleischer Aurélien Merot Michael Erhardt & Boris Mathys
